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Abstract: The efficacy and safety of vitamin K antagonists (VKAs) as oral anticoagulants (OACs)
depend on the quality of anticoagulation control, as reflected by the mean time in therapeutic range
(TTR). Several factors may be involved in poor TTR such as comorbidities, high inter-individual
variability, interacting drugs, and non-adherence. Recent studies suggest that gut microbiota (GM)
plays an important role in the pathogenesis of cardiovascular diseases, but the effect of the GM on
anticoagulation control with VKAs is unknown. In the present review article, we propose different
mechanisms by which the GM could have an impact on the quality of anticoagulation control in
patients taking VKA therapy. We suggest that the potential effects of GM may be mediated first, by
an indirect effect of metabolites produced by GM in the availability of VKAs drugs; second, by an
effect of vitamin K-producing bacteria; and finally, by the structural modification of the molecules
of VKAs. Future research will help confirm these hypotheses and may suggest profiles of bacterial
signatures or microbial metabolites, to be used as biomarkers to predict the quality of anticoagulation.
This could lead to the design of intervention strategies modulating gut microbiota, for example, by
using probiotics.
Keywords: oral anticoagulants; gut microbiota; microbial metabolites; vitamin k; trimethylamine
n-oxide
1. Introduction
For many years, the only options available for oral anticoagulation (OAC) therapy
were the vitamin K antagonists (VKAs), and they are still widely used for several conditions.
The most common indication is stroke prevention in atrial fibrillation (AF) [1], so the
majority of AF patients require long-term OAC, as suggested by guidelines [2,3]. Despite
the introduction of direct-acting oral anticoagulants (DOACs), the use of VKAs in AF
is common in some countries, for example in Eastern Europe and Southern Europe [4].
Aside from AF patients, there is also a wide range of patients for whom VKAs are the
recommended OAC therapy, for example, AF patients with rheumatic mitral stenosis and
the presence of mechanical valvular prostheses [3,5]. In these patients, evidence about the
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safety and efficacy of DOACs is limited, and VKAs are the most commonly used therapy,
thus highlighting the need for good quality anticoagulation control in these VKA users [6].
Similarly, in patients with history of thrombosis and diagnosed with antiphospholipid
syndrome (APS), the use of rivaroxaban was associated with an increased risk of recurrent
thrombotic events, compared with warfarin [7]. In the absence of evidence for apixaban,
edoxaban, and dabigatran, all DOACs are not recommended in patients with APS, particu-
larly in high-risk patients (those who present a positive test for all 3 antiphospholipid tests:
lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2 glycoprotein I antibodies).
In addition, APS patients taking a DOAC should be carefully evaluated and the possibility
of switching to a VKA should be considered. Thus, VKA therapy remains the first-line
treatment for a first or recurrent APS-related venous thrombotic event [8]. Finally, DOACs
are currently more expensive than treatment with VKA and in the context of venous
thromboembolism (VTE), there is no reimbursement for DOACs in several countries [9,10].
Consequently, an important proportion of VTE patients who could be potential users of
DOACs are actually taking VKAs.
In patients who are prescribed VKAs, the quality of anticoagulation control is central
to prevent bleeding and thromboembolic events [11]. There is evidence for gut microbiota
influencing the progression or development of some cardiovascular diseases [12,13], but
there are limited data linking gut microbiota to the quality of anticoagulation in VKA users.
The aim of the present review is to summarize published data on the potential impact of
the gut microbiota on the quality of anticoagulation of patients receiving VKA therapy, and
to suggest different hypotheses that could associate intestinal bacterial with VKA.
2. Main Text
2.1. Search Strategy and Selection Criteria
Data for this review were identified by searches of PubMed, and references from
relevant articles using the search terms “oral anticoagulants,” “vitamin K antagonists,”
“gut microbiota,” “microbial metabolites,” “vitamin K,” and “trimethylamine N-oxide.”
Articles published in English and Spanish between1980 and 2020 were reviewed and
included, if appropriate.
2.2. Quality of Anticoagulation with VKA
Underuse and premature discontinuation of OAC is common, and VKAs have a major
inter- and intra-individual variability with a narrow therapeutic window [14]. Also, regular
monitoring is required to maintain the International Normalized Ratio (INR) between 2.0
and 3.0 (therapeutic range), to ensure a time in therapeutic range (TTR) ≥65–70% [3,15].
Nevertheless, half of VKAs users have poor anticoagulation control [16], resulting
in an increased risk of thromboembolic and bleeding events, including ischemic stroke,
major bleeding, major adverse cardiovascular events (MACEs), and all-cause (and cardio-
vascular) mortality [11]. Several factors may predispose to poor TTR, including interacting
drugs, non-adherence to therapy, and concomitant conditions [17] (Table 1), as well as
dietary factors.
In addition, VKAs inter-individual variability is often so high that it is difficult to
clarify why TTR decreases or why an optimal TTR is never achieved. Therefore, one
possibility may be due to diet and the influence of gut microbiota.
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Table 1. Factors affecting the quality of vitamin K antagonist therapy.
Co-Medication
Antiplatelet drugs






History of atherosclerotic stroke
History of major bleeding
Uncontrolled hypertension
Genetic Factors
Mutation in factor IX propeptide (low factor IX levels)





Absence of familiar or social support
Alcohol abuse
Insufficient information and education to the treatment
Nutritional supplements and herbal products
Poor compliance
Poor dietary intake of vitamin K
Tendency to falls
VKAs: vitamin K antagonists.
2.3. Gut Microbiota and Xenobiotic Metabolism
The human microbiome is composed of a consortium of bacteria, viruses, archaea,
eukaryotic microbes and their genomes in dynamic and symbiotic equilibrium with host
cells [18,19]. This ecological community of symbiotic, commensal, and pathogenic microor-
ganisms has a potential role contributing to health and disease [20]. The microbiota is
known to impact human physiology, protect against pathogens, contribute energy home-
ostasis, neurodevelopment, extract nutrients from the diet [21], metabolism, and normal
immune functions [19,22].
Microbial cells that colonize the human body, including skin and mucous membranes,
are as abundant as our somatic cells, being estimated between 500 and 1000 species of bacte-
ria. The densest habitat in the human body is the gut, with high microbial biomass (0.15 kg)
with the Firmicutes and Bacteroidetes as dominant phyla [23]. The human microbiome is
highly personalized, with a unique composition in each individual and some factors can
profoundly affect the structure of the microbial community, such as diet, lifestyle, and
antibiotics. Moreover, the human microbiome is highly dynamic and its composition can
vary over short-term and long-term timescales. In early life, for example, the establishment
and composition of gut microbiota during infancy is affected by the type of infant feeding,
birth mode, older siblings, and maternal or infant antibiotic use [24]; subsequently, after
the first year of life, the gut microbiota increases dramatically in diversity and stability.
Microorganisms modify many classes of dietary components, such as lipids, proteins,
polysaccharides, phytochemical complexes or small molecules (xenobiotics) [25]. They also
transform industrial chemicals, altering their toxicity and lifetimes in the body. As for drugs,
the bacteria can change their pharmacokinetics and pharmacodynamics, affecting critically
the activation of the prodrug, its biological effect and half-life, as well as bioavailability,
resulting in adverse effects or loss of effectiveness. Most human microbiota-xenobiotic
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interactions are performed in the gastrointestinal tract, where there are regions with
different pH, oxygen levels, cellular physiology, and amounts of nutrients [26].
The combined metabolisms of host and microbiota can produce metabolites that may
alter the lifetime and bioactivity of xenobiotics in the human body [27,28]. At the enzymatic
level, the host mainly uses oxidative and conjugative chemical reactions. Human xenobiotic
metabolism often transforms non-polar compounds into hydrophilic metabolites that are
more easily excreted, a process that occurs in two phases [29].
The xenobiotic compounds that are ingested orally pass into the small intestine,
suffering enzyme-mediated modifications and being absorbed by host tissues. Before
xenobiotics are transported to the liver through the portal vein, they pass through or
between intestinal epithelial cells, undergoing enzymatic processes [30]. After the exposure
to liver enzymes, xenobiotics and their metabolites pass into the systemic circulation, being
distributed through tissues and distal organs. In the circulatory system, they are excreted or
metabolized, either by biliary excretion or through the kidneys. Metabolites that returned
to the light of the intestine are excreted with the feces or can be reabsorbed by enterohepatic
circulation and transformed by gut bacteria [31,32]. Compounds administered by other
pathways, for example by intravenous injection or easily absorbed compounds, can be
also exposed to the action of gut microorganisms [33]. At the same time, metabolites
produced by intestinal microorganisms can circulate systemically [34], interacting with
epithelial cells of the gastrointestinal tract locally or be absorbed by the host and eliminated
by feces or urine [35], generating a complex metabolic network that affects both, the host
and the microbiota itself. Within the distinctive and complex ecology of the human gut,
microorganisms transform ingested substrates through a wide range of enzymatic reactions,
with inter-individual variability in the ability to transform or metabolize xenobiotics [36].
Despite the consequences of these modifications, little is known about the individual
microbes and enzymes involved in these reactions.
Given the above evidence, we explore three different hypotheses about the potential
impact of the gut microbiota on the quality of anticoagulation in patients receiving an-
ticoagulant therapy with VKAs. First, an indirect effect of metabolites produced by gut
microbiota in the availability of VKAs drugs; second, an effect of vitamin K-producing
bacteria; and third, structural modification of the VKA drug molecule (Figure 1).
2.3.1. Effect of Metabolites Produced by Gut Microbiota on VKAs Drugs
Gut bacteria generally exert reducing and hydrolytic reactions [37]. Enzymes as-
sociated with gut microorganisms are oxydoreductases, hydrolases, transferases, and
lyases [38], widely distributed in a variety of bacterial groups, although enzymes with high
similarity between families can catalyze different chemical reactions.
The gut microbiome metabolizes non-digestible dietary components [39] and partici-
pates in immune function [40] and/or bioactivation of nutrients and vitamins. However,
not all the microbial enzymes involved in these chemical transformations have been
described. Indeed, not all metabolic activities or functional profiles in these microbial
communities can be predicted in metabolomic studies [41]. Thus, metabolic functions
are assigned to superfamilies that can catalyze several different chemical reactions. One
of the more interesting abilities of intestinal bacteria is the synthesis of metabolites pro-
duced directly by the gut microbiota or by the metabolism of dietary components, such as
trimethylamine N-oxide (TMAO), indoxyl sulfate (IS), and indole-3 acetic acid (IAA) [42].
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Figure 1. Potential impact of the gut microbiota in vitamin K antagonists. Three hypotheses about the
role of the gut microbiota on the quality of anticoagulation in patients taking vitamin K antagonist
therapy: (i) Effect of microbial metabolites in the bioavailability of VKAs; (ii) bacterial production of
vitamin K and; (iii) structural modification of VKA molecules. Abbreviations: AF, atrial fibrillation;
APS, antiphospholipid syndrome; VHD, valvular heart disease; VKAs, vitamin K antagonists, VTE,
venous thromboembolism.
Trimethylamine N-Oxide (TMAO)
Concerning metabolites, intestinal bacteria metabolize part of the main group of
phosphatidylcholine, in the metabolic via phosphatidylcholine-choline, producing an
intermediate compound known as trimethylamine (TMA). TMA is generated from dietary
compounds such as betaine, L-carnitine, and its metabolite γ-butyrobetaine (GBB), choline,
and other choline-containing compounds [43].
Choline is an essential nutrient, contributing to neurotransmission, methyl transfer
events, and cell membrane function. It is found in high quantities in food stuffs such
as peanuts, eggs, meat, beef liver, and cauliflower [44]. It is obtained as free choline
from foods of animal origin or as part of various compounds such as phosphocholine,
phosphatidylcholine, and sphingomyelin. Free choline is absorbed throughout the small
intestine and it is integrated into cell membranes or absorbed by the liver, where it can be
converted to lecithin, phosphocholine, or betaine [45]. If the amount of choline exceeds the
absorption capacity, it passes to the large intestine where it is metabolized by microbial
action to methylamines [46] (Figure 2).
On the other hand, L-carnitine is converted into TMAO by the action of carnitine
oxidoreductase. Next, TMA is rapidly oxidized by hepatic flavin-containing monooxyge-
nases (FMO1–FMO3) to form TMAO [47]. Figure 3 summarizes the principal pathways
and enzymes involved in the production of TMA and TMAO.
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Figure 2. Formation of trimethylamine (TMA) and trimethylamine N-oxide reductase (TMAO). The key enzymes responsible
indicated are: carnitine monooxygenase (CntAB); choline-TMA lyase (CutCD); glycine betaine reductase (GrdH); and Ergothionase.
Choline to glycine betaine is mediated by the Bet pathway (BetA). FMOs: flavin-dependent monooxygenase (isoforms 1,3).
Clinical effects: : activation, : producing and secretion.
Figure 3. Principal pathways to formation of trimethylamine (TMA) and trimethylamine N-oxide reductase (TMAO).
There is a recognized association between TMAO and inflammation [48–52]. Indeed,
TMAO triggers vascular inflammation by activation of caspase 1, producing and secreting
pro-inflammatory cytokines (IL-1β and IL-18) and activating the NACHT, LRR, and PYD
domains-containing protein 3 (NLRP3) inflammasome [53]. Activation of inflammasome
has been linked to heart failure, adverse heart remodeling, and cytokine-mediated systolic
dysfunction. The effects of TMAO on the components of the intrinsic cardiac autonomic
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nervous system (Ganglionated Plexi (GP) [54]) have been associated with increased expres-
sion via pro-inflammatory signaling and the nerve growth factors [53]. Whether circulating
TMAO derived from the intrinsic microbiome can reach the GPs or not by creating sufficient
local concentrations to give rise to arrhythmogenic effects [55] remains to be confirmed.
Likewise, elevated levels of TMAO in plasma increase the risk of developing atheroscle-
rosis [56] and other adverse cardiovascular events, such as stroke, myocardial infarc-
tion, and death [47]. Recent studies in primary human coronary artery endothelial cells
(HCAECs) isolated from normal human coronary arteries demonstrated that TMAO pro-
moted nuclear translocation of nuclear factor-κB (NF-κB) and expression of tissue factor
(TF), implicated in the thrombogenicity of atherosclerotic plaque [57]. Low-dose TMAO
also significantly promoted low-dose of tumor necrosis factor-alpha (TNF-α) [58] or high
mobility group box 1 (HMGB1) mediated by TF expression via activating NF-κB signaling
and finally, studies in ST-elevation myocardial infarction patients, linking increased plasma
concentrations TMAO with increased TF activity [59].
Indoxyl Sulfate (IS) and Indole-3 Acetic Acid (IAA)
Indoxyl sulfate (IS) is a protein-bound uremic solute resulting from bacterial metabolism
of dietary tryptophan to indole by the action of bacterial tryptophanases, absorbed into the
systemic circulation [60]. Indole is metabolized by the liver to an IS form, subsequently
excreted by the kidneys by organic anion transporter OAT1 and OAT3. On the other hand,
indole-3 acetic acid (IAA) is a protein-bound small molecule, also derived from tryptophan
metabolism but it is also produced by cells and excreted by tubular secretion mediated by
the OAT1 transporter. IS, is an agonist of the transcription factor aryl hydrocarbon receptor
(AhR) which regulates the cell response to environmental xenobiotics. IAA may lead to a
procoagulant effect, induces endothelial tissue factor expression, and increases the mRNA
expression of the enzyme cyclooxygenase-2 (COX-2), which is primarily responsible for
the synthesis of inflammatory prostanoides [61,62].
In vitro IAA studies on cultured endothelial cells demonstrated proinflammatory
and prooxidant effects, increasing ROS production and the expression of endothelial
inflammatory genes: MCP-1, IL-6, IL-8, ICAM-1. Furthermore, AhR activation is associated
with oxidative stress, atherogenesis, and vascular inflammation, as well as activation
of an inflammatory signaling pathway with p38 MAPK and NF-κB involved in COX-2
upregulation [63].
IS and IAA may contribute to vascular disease progression by AhR activation and in-
creased tissue factor expression in vascular smooth muscle, peripheral blood mononuclear,
and endothelial cells [62,64]. The transmembrane glycoprotein TF functions as a high-
affinity receptor for FVII and FVIIa factors when TF is exposed to circulation initiates an
extrinsic coagulation cascade, so the TF-FVIIa complex is considered the primary activator
of the coagulation protease cascade. To allow FVIIa optimal interaction with the substrates
FX and FIX, TF is needed to stabilize the catalytic site of FVIIa on a plasma membrane [65].
Extrinsic coagulation can be divided into three phases: TF-FVIIa-dependent initiation,
inhibition of the TF-FVIIa complex by TF pathway inhibitor (TFP(I)), and amplification
of thrombin generation. In acute atherosclerotic thrombosis, especially acute myocardial
infarction, activation of TF is dispensable in the TF-mediated coagulation [57].
Given recent studies on the ability of bacterial metabolites such as TMAO, IS, or IAA
to promote the progression or development of cardiovascular diseases, they may have a
possible role associated with increased cardiovascular risk.
2.3.2. Effect of Vitamin K-Producing Bacteria
Vitamin K maintains normal blood coagulation. The K-dependent coagulation proteins
formed in the liver have coagulant and anticoagulant properties and include factors FII,
FVII, FIX, and FX (coagulant role) and proteins C and S (anticoagulant role). It is also
involved in the pathway of the glutamate conversion to gamma-carboxyglutamate residues,
to form prothrombin. VKAs act as indirect anticoagulants and their principal mechanism
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of action is based on the inhibition of the vitamin K oxide reductase (VKOR). The gene
that codified the VKOR protein, encodes for several isoforms of a protein denominated
“vitamin K oxide reductase complex 1” (VKORC1), and its pharmacodynamic is influenced
by the vitamin K epoxide reductase (VKORC). VKORC enzyme converts oxidized vitamin
K to the reduced active form, and this form is required for the post-translational (gamma)
carboxylation of coagulation factors (vitamin K-dependent) [66,67]. Thus, by blocking the
reuse of the epoxidemetabolite, VKAs induce, relative, vitamin K deficiency in the cells
that synthesize Gla proteins.
There are different forms of vitamin K. Phylloquinone or vitamin K1 is a single
compound with a side chain of four isoprenoid residues, three of which are saturated.
On the contrary, the menaquinones have side chains of varying length between four and
thirteen isoprene residues, most of which are unsaturated [68]. The forms of vitamin
K serve as cofactors for the post-translational enzyme γ-glutamate carboxylase. This
enzyme converts certain protein-bound glutamate residues into γ-carboxyglutamate or
Gla. Seven Glaproteins are involved in blood coagulation (major actors of coagulation
cascade) and others are extrahepatically synthesized: osteocalcin (Oc); matrix Gla protein
(MGP); Gla-rich protein (GRP); proline-rich Gla proteins (PRGP); 1,2, periostin(isoforms
1–4)/periostin-like-factor (PLF); transmembrane Gla protein (TMG) 3 and 4; and growth
arrest specific protein 6 (Gas6) [69]. However, the real physiological importance of these
Glas proteins is uncertain.
After intestinal absorption of vitamin K, vitamin K forms are bound to TAG-rich
lipoproteins and are transported to the liver and other target tissues. The forms of vitamin
K have different pharmacokinetics, with variable plasma half-life times and different tissue
distribution. For example, the vitamin K2 MK-7 has a half-life of several days (2–3 days),
with higher bioavailability and absorption, whereas vitamins K1 and K2 MK-4 quickly
disappear from circulation in the body (half-life of 1 to 2 h) [70].
Diet has an important role in the stability of VKA therapy. For example, patients
increasing the intake of vitamin K in the diet may become resistant to the effect of VKAs
whereas lower vitamin K intake increases sensitivity to VKAs. Hence, instability in the
control of anticoagulation in patients taking VKAs may also be attributable to low vitamin
K reserves or poor dietary intake. In clinical trials, vitamin K supplementation is effective
for the improvement of the quality of anticoagulation [71].
Why is vitamin K important in patients taking VKA therapy? For patients taking
OAC therapy with VKAs, dietary recommendations are based on controlling the intake
of vitamin K1 or phylloquinone, present in green leafy vegetables [72,73]. Some forms of
vitamin K2 or menaquinones that are present in cheese, natto (Japanese food), and curd,
are produced generally by some bacteria genera of the gut microbiota, and 10–25% of total
vitamin K intake is derived from menaquinones [74]. Moreover, most anaerobic and aerobic
Gram-positive bacteria in the gut use menaquinones in their electron transport pathways.
The length of the side chain of menaquinone depends on the growth temperature of a
specific bacterial species.
Some examples of menaquinone-producing bacteria are: Eubacterium lentum which
produces MK-6, Lactococcus lactis ssp. lactis and spp. cremoris that mainly produce MK-8
and MK-9, Bacteroides fragilis which produces MK-10, MK-11, and MK-12, whereas some
species of the genus Propionibacterium mainly produce MK-9 [75].
The absorption routes of menaquinones produced by bacteria are unclear. The absorp-
tion of all forms of vitamin K occurs in the small intestine, in a process mediated by bile
salts. Nevertheless, most menaquinones are produced in the colon, where the bile salts are
absent, suggesting a low absorption of these forms of vitamin K. Some studies in experi-
mental animals [76] and formula milk-fed babies [77] confirm this theory, demonstrating
that the absorption of menaquinones intestinally produced is low. Another important
factor is that the majority of menaquinones are not bioavailable, as they are inside the
membranes of the bacteria that produce them. There may be a role in the coagulation
process in patients with prolonged vitamin K deficiency [78].
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In some studies [79,80], the effects of menaquinone MK-7 and MK-9 on coagulation
parameters have been reported. These studies showed that MK-7 and MK-9 decreased
the concentrations of coagulation factors and INR, the effect as an antidote for OAC was
stronger for MK-7, being 3 to 4 times more potent for VKAs [81].
Other gut bacteria have been previously identified as menaquinones producers of
various chain lengths, such as Bacteroides ovatus, Enterococcus faecalis, Escherichia coli, Pre-
votellabuccae, Staphylococcus epidermidis, and Staphylococcus haemolyticus. Some strains
isolated from feces of exclusively formula-fed infants were reported as vitamin K produc-
ers, e.g., Bacteroides spp., Citrobacter freundii, Enterobacter agglomerans, Enterococcus faecium,
Serratia marcescens, Staphylococcus capitis, and Staphylococcus warneri, these bacterial strains
are predominantly facultative anaerobes associated with the young neonatal gut where the
environment is more anaerobic [82].
The ability to produce vitamin K allows us to consider the taxonomic composition
of the gut microbiota (mediated by vitamin K-producing species) as important factors
influencing the anticoagulant effect amongst VKA users.
2.3.3. Structural Modification of the VKAs Molecules by Gut Bacteria
After administration, drug molecules usually undergo chemical modifications and
therefore the final metabolites can have different pharmacological properties than the initial
molecule [83]. The majority of medications are given orally and they may be exposed
to commensal bacteria in the small or large intestines. As for pharmaceutical products,
the gut microbiota can transform some drugs by producing metabolites with altered
pharmacological properties. Research in this field has determined a complex interaction
between drugs-microbiota, either by direct or indirect chemical modification, through the
many interactions these organisms have with host cells in this environment [84–86].
Previously, some studies have shown interactions between drugs/metabolites and
the gut microbiome. For example, many anti-inflammatory agents depend on micro-
bial metabolism to convert inactive precursors (prodrugs) into pharmaceutically active
compounds. In the case of sulfasalazine, intestinal microbiota reduces sulfasalazine into
sulfapiridine and the active anti-inflammatory agent 5-acetylsalycilic acid (5-ASA) [87] via
azoreductase. Some bacterial genera such as Bacteroides, Clostridium, and Eubacterium have
been associated with the production of Azo reductases [88,89]. Another case of prodrug ac-
tivation by gut bacteria includes a sulfoxide reduction in the anti-inflammatory compound
sulindac and N oxide reduction of the antidiarrheal drug loperamide [90].
In relation to drugs used in cardiology, the best example is perhaps the Digitalis
purpurea plant (dedalera), used for years in the treatment of congestive heart failure. The
active compound is a cardiac glycoside digoxin [91], which inhibits Na+/K+ATPases in
cardiac myocytes, producing calcium influx and increasing muscle contraction. In studies
where antibiotics and digoxin were administered together, dihydrodigoxin production was
decreased or eliminated, suggesting a decisive role of the intestinal microbiota in drug
inactivation. In 2013, Haiser et al. [92] identified a group of digoxin-inducible genes, only
present in Eggerthellalenta strains that metabolize digoxin. The cardiac glycoside reductase
(cgr) operon from this bacteria, encodes two proteins similar to reductases (Cgr1 and Cgr2)
mediating the conversion of digoxin to dihydrodigoxin. These results derived in a dietetic
intervention designed for reducing the metabolism of digoxin in vivo.
Another example of microbe-mediated alteration is the uptake and availability of
amiodarone (Class III antiarrhythmic). The co-administration of the probiotic bacterium
Escherichia coli Nissle 1917 serotype O6: K5: H1 (EcN) has been used for the prevention and
treatment of some diseases and intestinal disorders such as irritable bowel syndrome, in-
flammatory bowel disease, and protracted or chronic recurrent diarrhea. EcN can influence
the amiodarone pharmacokinetics, increasing its bioavailability. In vivo studies confirmed
that EcN increases the bioavailability and absorption of amiodarone [93].
It has been also demonstrated the ability of some bacterial species to chemically modify
warfarin [94]. The authors evaluated the drug-metabolizing activity of human gut bacteria
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in 271 drugs, and they found that about two-thirds of the assayed drugs were metabolized
by at least one bacterial strain; this drug-metabolizing activity mediated by the microbiota
depends on the drug and its formulation. In the case of warfarin, four bacterial species, such
as Anaerotruncuscolihominis DSM17241, Bacteroides vulgatus ATCC8482, Collinsellaaerofaciens
ATCC25986, and Edwardsiellatarda ATCC23685 were linked to the ability to metabolize this
drug. These studies support the theory of possible impact on drug-metabolite exposure,
affecting the intestinal and systemic drug metabolism.
2.4. Outstanding Questions
With the establishment of the heart-gut axis concept, several studies suggest an im-
portant role of the gut microbiota in the pathogenesis of cardiovascular diseases. However,
there are limited studies indicating a direct association between gut microbiota and VKAs.
Recently, Miamo et al. collected samples from 200 undergoing heart valve replacement
patients and the different responses to warfarin anticoagulation therapy were classified as;
low, normal, and high responder. The authors observed that the genus Escherichia-Shigella
and the genus Enterococcus were significantly enriched in the low and high response groups,
respectively. When the vitamin k content was measured in stool and blood samples, syn-
thesized VK2 and the relative abundance of modules associated with VK biosynthesis and
enzymes were higher in the low responder group when compared to normal and high
responder [95].
Given this limited data, the possible relationship between gut bacteria and the quality
of anticoagulation is still an unexplored field and should be addressed from different per-
spectives, such as the comparison of microbial profiles in patients with poor and optimal
TTR; the identification of microbial signatures using profiled metabolites; and the identifi-
cation of possible circulating microbial biomarkers to predict a successful VKA treatment.
Overall, our overview suggests a potentially novel causal role of gut microbiota in
contributing to the quality of anticoagulation with VKAs users. Herein, we propose that
the gut microbiota and microbial products can establish a relationship with the VKA, and
we suggested a novel role of the intestinal microbiota as a key factor for interindividual
variability in the quality of anticoagulation. It could be assumed that the increase in some
specific groups of the gut microbiota may induce metabolic activity that affects the quality
of anticoagulation, either by the production of secondary bacterial metabolites, by bacterial
groups producing menaquinones, or by structural modification of the anticoagulants
drugs. In the future years, new studies focused on the integration of metagenomic and
metabolomic analyses may suggest profiles of bacterial signatures or microbial metabolites,
to be used as biomarkers to predict the quality of anticoagulation. This could lead to
the design of intervention strategies modulating gut microbiota, for example by using
probiotic bacteria.
The potential impact of probiotics on the composition of the gut microbiota could
be to regulate the synthesis of TMAO precursor molecules in the gut [96]. At the same
time, this could decrease the impact on endothelial inflammatory injury, the production
of pro-inflammatory cytokines, oxidative stress, and endothelial dysfunction, as well
as increased adhesion of monocytes, all associated with TMAO production. A study
with potential probiotic bacterial species in mice demonstrated that Lactobacillus plantarum
ZDY04 significantly reduces serum TMAO and cecal TMA levels by modulating the relative
abundance of the families Bacteroidaceae, Erysipelotrichaceae, Lachnospiraceae, and genus
Mucispirillum [97].
3. Conclusions
In anticoagulated patients with VKAs, the quality of anticoagulation control is central
to avoiding thromboembolic and bleeding complications. In the search of potential factors
affecting the quality of VKAs, gut microbiota, which have shown to play an important
role in several cardiovascular diseases, could also have an impact on the response to VKA
therapy. This could be the result of an indirect effect of metabolites produced by gut
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microbiota in the availability of VKAs drugs, an effect of vitamin K-producing bacteria,
or by the structural modification of the molecule of VKAs drug. In order to implement
predictive or preventive strategies before VKA therapy, there is a need for studies directly
investigating the role of gut bacteria and their metabolites on this family of drugs. The use
of probiotics could be proposed as an alternative given the modulation of gut microbiota
compositions and their metabolic pathways. The main strategy is based on modulating the
intestinal ecosystem using bacterial species with the ability to compete for the colonization
of the intestinal epithelium or with antimicrobial or antagonist activity against metabolite-
producing bacteria such as TMAO, vitamin K-producing bacteria, or bacterial with the
ability to structurally modify the molecules of VKAs.
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